Research
Hormonal
Semaglutide 2.4 mg weekly reduces cardiovascular mortality, myocardial infarction, and stroke in overweight/obese patients without diabetes but with cardiovascular disease.
If you have obesity and existing heart disease, even without diabetes, semaglutide 2.4 mg weekly can significantly reduce your risk of heart attack, stroke, and death. This is a critical benefit beyond weight loss. Discuss this with your doctor to see if you qualify for this treatment.
StrongSupportsVERY_HIGH confidence
The SELECT study demonstrated benefits in reducing cardiovascular mortality, myocardial infarction, and stroke with weekly doses of 2.4 mg semaglutide compared to placebo in overweight or obese patients without diabetes but with underlying cardiovascular disease
Why this rating
Based on the SELECT study, a major randomized controlled trial.
Source
Obesidad, el papel del gastroenterólogo
Valeria Atenea Costa et al. · Revista Colombiana de Gastroenterología · 2024
narrative_reviewCited 1×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →